Table 2.
The selected demographic, clinical and laboratory data of vaccinated hemodialysis patients divided into subgroups
| Parameter | Group I (n = 602) | P value for differences between Ia and Ib | |
|---|---|---|---|
| Subgroup Ia (n = 199) | Subgroup Ib (n = 403) | ||
| Men, n (% of all) | 103 (51.8) | 228 (56.6) | 0.296 |
| Age, years | 69.6 (23.8–92.5) | 62.8 (18.6–91.7) | <0.001 |
| RRT duration, years | 1.0 (0.03–11.6) | 2.8 (0.003–26.1) | <0.001 |
| Diabetic nephropathy, n (% of all) | 72 (36.2) | 102 (25.3) | 0.007 |
| Chronic glomerulonephritis, n (% of all) | 11 (5.5) | 78 (19.4) | <0.001 |
| Hypertensive nephropathy, n (% of all) | 40 (20.1) | 67 (16.6) | 0.308 |
| Chronic tubulointerstitial nephritis, n (% of all) | 18 (9.0) | 35 (8.7) | 0.880 |
| An anti-HBs titre >10 IU/L | – | 403 (100 %) | NA |
| Positive anti-HCV, n (% of all) | 11 (5.5) | 37 (9.2) | 0.150 |
| Positive both anti-HCV and HCV RNA (n, % of all anti-HCV positive) | 5 (45.5) | 25 (67.6) | 0.288 |
| ALT (IU/L) | 13 (0.6–126) | 13 (2–209) | 0.222 |
| AST (IU/L) | 14 (5–97) | 15 (4–177) | 0.309 |
| GGT (IU/L) | 30 (5–308) | 25 (0–472) | 0.590 |
Continuous variables are expressed as median and range. Significant results are indicated using bold font
ALT alanine aminotransferase, anti-HBs antibodies to surface antigen of hepatitis B virus, anti-HCV antibodies to hepatitis C virus, AST aspartate aminotransferase, GGT gamma-glutamyltranspeptidase, HCV RNA ribonucleic acid of hepatitis C virus, NA not applicable, RRT renal replacement therapy